Thanks Bw, H.C. Wainwright analyst Yi Chen raised the firm's price target on CytoDyn to $4 from $3 and reiterates a Buy rating on the shares after the company submitted the clinical and the chemistry, manufacturing and controls portions of the Biologics License Application to the FDA for leronlimab as a combination therapy with highly active antiretroviral therapy for highly treatment experienced HIV patients. Following this "derisking event" and in light of leronlimab's newly-discovered effectiveness in treating COVID-19, the analyst increased the probability of approval in COVID-19 to 50% from 35%.

Read more at:
https://thefly.com/landingPageNews.php?id=308...Wainwright